Network Meta-Analysis: Importance of Appropriate Trial Selection  by Edwards, Steven J. & Borrill, John
Network Meta-Analysis: Importance of Appropriate
Trial Selectionvhe_715 681..682
To the Editor—Network meta-analysis (NMA) is a technique
that is increasingly employed in health technology appraisal to
generate comparative efﬁcacy and safety data for treatments not
compared directly in randomized controlled trials. The National
Institute for Health and Clinical Excellence (NICE) has recom-
mended its use when direct comparator trials are unavailable [1].
As discussed in the article by Hawkins et al. [2], it is important to
include all relevant and informative data in an NMA. Inappro-
priate study selection can have a huge impact on results and lead
to erroneous conclusions. This would appear to be the case in the
selection of studies for the extended NMA presented in this
article.
The objective of the clinical example was to assess overall
survival with erlotinib compared with docetaxel in the second-
line treatment of stage III/IV non–small-cell lung cancer
(NSCLC). When presented with the extended NMA as part of
the single technology appraisal of erlotinib in the treatment of
NSCLC, the NICE appraisal committee raised concerns about
the lack of comparability of patient populations for some of the
studies included within the network [3]. For example, the Iressa
Survival Evaluation in Lung Cancer (ISEL) trial [4] comparing
geﬁtinib versus placebo, the largest trial in the extended network
and the main driver of the different conclusions between the
limited and the extended NMAs, included a very high proportion
of chemotherapy refractory patients (90%). The refractory
nature of the ISEL population may account for the failure of this
study to show superiority versus placebo in terms of overall
survival, although the BR21 trial of erlotinib versus placebo
succeeded in a less refractory population. Hence, inclusion of the
ISEL trial may violate the exchangeability assumption in the
NMA. In addition, as presented in Table 2 in the Hawkins et al.
article, ISEL and BR21 [5] included a substantial proportion of
patients that had received more than one previous chemotherapy
(50% in both studies). This third-line setting is not consistent
with the second-line objective of the analysis.
The consistency of the study populations and the number of
previous treatments received are key features that need to be
assessed when making an assumption of exchangeability of data
within an NMA. Based on the study population, it could be
argued that the ISEL trial should be excluded from the NMA. If
it is to be included, however, data on second-line only patients
should be used from both this and the BR21 study. These data, as
well as the relevant second-line data from the other trials
included in the extended NMA, are presented in Table 1.
Based on the second-line data, an NMA, using docetaxel as a
baseline for comparison, produces the results presented in
Table 2. All four active treatments have similar survival to each
other, and best supportive care has a shorter survival. The very
different conclusions from this analysis, the limited NMA, and
the extended NMA presented by Hawkins et al. illustrate the
high sensitivity of the modeling results to the selection of studies
included.
We welcome the methodological recommendations for NMA
presented by Hawkins et al. that have been highlighted by pre-
vious researchers [12,13]. In implementing this NMA, however,
we stress the importance of appropriate study selection: studies
included should be relevant to the objective of the analysis and
include comparable patient populations such that the exchange-
ability assumption is met. This is particularly important when
only a few studies provide information on each of the treatments
included in the NMA, as in this example (ﬁve comparators from
six studies), as inclusion of inappropriate data can have undue
weight on the results.
NMA can be a useful tool when direct comparative data are
not available, but randomized controlled trials remain the gold
standard for comparing the efﬁcacy and safety of two
treatments.—Steven J. Edwards, DPhil, and John Borrill, MSc,
AstraZeneca UK Ltd, Luton, Bedfordshire, UK.
Source of ﬁnancial support: Steven J. Edwards and John Borrill are
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Table 1 Hazard ratios (HRs) for overall survival for randomized controlled trials informing the network meta-analysis for second-line treatments for
stage III/IV non-small cell lung cancer (HR < 1 treatment is better than comparator; HR > 1 treatment is worse than comparator)
Trial Treatment Comparator HR (95% conﬁdence interval) Log HR (SE)
BR21 [5,6] Erlotinib BSC 0.76 (0.60–1.10) -0.27 (0.15)
JMEI [7] Pemetrexed Docetaxel 0.99 (0.82–1.20) -0.01 (0.10)
TAX 317 [8] Docetaxel BSC 0.48 (P = 0.004) -0.73 (0.25)
ISEL [4,9] Geﬁtinib BSC 0.80 (0.66–0.97) -0.22 (0.10)
INTEREST [9,10] Geﬁtinib Docetaxel 0.96 (0.85–1.08) -0.04 (0.06)
SIGN [11] Geﬁtinib Docetaxel 0.97 (0.61–1.52) -0.03 (0.23)
BSC, best supportive care alone or with placebo; SE, standard error.
Table 2 Hazard ratios (HRs) for overall survival from the network
meta-analysis using docetaxel as the baseline treatment (HR < 1 is better
than docetaxel; HR > 1 is worse than docetaxel)
Treatment Mean
95% credible interval
Lower Upper
Docetaxel 1.00 Baseline Baseline
BSC 1.32 1.07 1.61
Geﬁtinib 0.98 0.87 1.10
Erlotinib 1.02 0.69 1.44
Pemetrexed 1.00 0.82 1.20
BSC, best supportive care alone or with placebo.
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